d/or alpha agonist drugs. when considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug. 7.3 local anesthetic agent when hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidences of systemic reaction. 7.4 salicylates, cortisone, acth, estrogens, antihistamines patients receiving large doses of salicylates, cortisone, adrenocorticotropic hormone (acth), estrogens, or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.

ch scapula, followed by injection of the contrast medium at the same sites. ( 2.4 ) 2.1 important administration instructions parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. vitrase should be administered as discussed below, since its effects relative to absorption and dispersion of other drugs are not produced when it is administered intravenously. draw the desired amount of vitrase into the syringe to obtain the target hyaluronidase activity (usp units) according to the table below. table 1: amount of vitrase solution withdrawn per target hyaluronidase activity target hyaluronidase activity (usp units) volume withdrawn from vial (ml) 50 units 0.25 ml 75 units 0.38 ml 150 units 0.75 ml 200 units 1.00 ml after admixture with drug, store at 15° to 25°c (59° to 77°f) and use within 6 hours. 2.2 dosage for subcutaneous fluid administration (hypodermoclysis) insert needle with aseptic precautions. with tip free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. then inject vitrase into rubber tubing close to needle. an alternate method is to inject vitrase under skin prior to clysis. 200 units will facilitate absorption of 1,000 ml or more of solution. as with all parenteral fluid therapy, observe effect closely, with same precautions for restoring fluid and electrolyte balance as in intravenous injections. the dose, the rate of injection, and the type of solution (saline, glucose, ringer’s, etc.) must be adjusted carefully to the individual patient. when solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur. this may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration. vitrase may be added to small volumes of solution (up to 200 ml), such as small clysis for infants or solutions of drugs for subcutaneous injection. for infants and children less than 3 years old, the volume of a single clysis should be limited to 200 ml; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 ml/kg of body weight; the rate of administration should not be greater than 2 ml per minute. for older patients, the rate and volume of administration should not exceed those employed for intravenous infusion. 2.3 dosage for absorption and dispersion of injected drugs absorption and dispersion of other injected drugs may be enhanced by adding 50–300 units, most typically 150 units of vitrase to the injection solution. 2.4 dosage for subcutaneous urography the subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. with the patient prone, 75 units of vitrase are injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites.

uticals north america llc, at 1-800-321-4576 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

d/or alpha agonist drugs. when considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug. 7.3 local anesthetic agent when hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidences of systemic reaction. 7.4 salicylates, cortisone, acth, estrogens, antihistamines patients receiving large doses of salicylates, cortisone, adrenocorticotropic hormone (acth), estrogens, or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.

y recognized pregnancies. clinical considerations hyaluronidase has been used as a component to aid the in vitro fertilization of human eggs. administration of hyaluronidase during labor was reported to cause no complications; no increase in blood loss or differences in cervical trauma were observed. 8.2 lactation risk summary there is no information regarding the presence of vitrasein human milk, the effects on breastfed infants, or the effects on milk production to inform risk of vitrase to an infant during lactation. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for vitrase, and any potential adverse effects on the breastfed infant from vitrase. 8.4 pediatric use the safety and effectiveness of vitrase have been established in pediatric patients. use of vitrase in these patients is supported by evidence from adequate and well-controlled studies. clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with vitrase. the dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. the potential for chemical or physical incompatibilities should be kept in mind [see drug interactions (7) ] . the rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. for premature infants or during the neonatal period, the daily dosage should not exceed 25 ml/kg of body weight, and the rate of administration should not be greater than 2 ml per minute. during subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion [see dosage and administration (2.2) ] . 8.5 geriatric use no overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

to avoid over hydration by controlling the rate and total volume of the infusion [see dosage and administration (2.2) ] .

of an insoluble serum albumen-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component. 12.2 pharmacodynamics in the absence of hyaluronidase, material injected subcutaneously spreads very slowly. hyaluronidase facilitates dispersion, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse. such an impulse is normally initiated by injected solutions. the rate and extent of dispersion and absorption is proportionate to the amount of hyaluronidase and the volume of solution. the reconstitution of the dermal barrier removed by intradermal injection of hyaluronidase (over a range of 0.002 to 20 units/ml) to adult humans indicated that at 24 hours the restoration of the barrier is incomplete and inversely related to the dosage of enzyme; at 48 hours the barrier is completely restored in all treated areas. results from an experimental study, in humans, on the influence of hyaluronidase in bone repair support the conclusion that this enzyme alone, in the usual clinical dosage, does not deter bone healing. 12.3 pharmacokinetics knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited. it is known, however, that the blood of a number of mammalian species including humans brings about the inactivation of hyaluronidase. studies have demonstrated that hyaluronidase is antigenic; repeated injections of relatively large amounts of this enzyme may result in the formation of neutralizing antibodies.